Zerlasiran

Improved screening for elevated lipoprotein(a) levels among all adults may improve CVD risk assessment and outcomes, especially with multiple Lp(a)-lowering therapies currently in the research pipeline, a speaker reported.

CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.

The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.